Skip to main content

Advertisement

Table 1 Demographic, clinical and serological features at baseline

From: Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus

Demographic features Value
 Female gender, n (%) 96 (89.7%)
 Caucasian, (%) 107 (100%)
 Onset age, median (IQR) years 31.3 (25.0–42.6)
 Age at diagnosis, median (IQR) years 34.3 (26.5–43.7)
 Disease duration at diagnosis, median (IQR) months 9.7 (6.0–27.6)
ACR 1997 clinical criteria
 Malar rash, n (%) 29 (27.1%)
 Discoid rash, n (%) 7 (6.5%)
 Photosensitivity, n (%) 26 (24.3%)
 Oral ulcers, n (%) 11 (10.3%)
 Arthritis, n (%) 96 (89.7%)
 Serositis, n (%) 32 (29.9%)
 Renal disorders, n (%) 27 (25.2%)
  Class Va 4 (3.7%)
  Class IVa 8 (7.5%)
  Class IIIa 6 (5.6%)
  Class IIa 3 (2.8%)
  Not biopsy proven 6 (5.6%)
 Neurologic disorders, n (%) 3 (2.8%)
 Haematological disorders, n (%) 61 (57.0%)
Disease activity
 SLEDAI-2K score, median (IQR) 10.0 (8.0-15.8)
  SLICC Damage Index, median IQRb 0 (0-0)
Serological features
 ANA, n (%) 106 (99.1%)
 Anti-dsDNA, n (%) 78 (72.9%)
 Anti-Sm, n (%) 19 (17.8%)
 Anti-RNP, n (%) 27 (25.2%)
 Anti-SSA, n (%) 46 (43.0%)
 Anti-SSB, n (%) 13 (12.1%)
 Any aPLs 26 (24.3%)
Treatment
 PDN dose at T0, median (IQR) mg/day 15.0 (6.5–26.9)
 PDN dose T0–T2, median (IQR) mg/day 10.4 (5.7–18.2)
 Anti-malarial drug, n (%) 67 (62.6%)
 Immunosuppressant drug, n (%) 68 (63.5%)
  Methotrexate, n (%) 24 (22.4%)
  Cyclophosphamide, n (%) 21 (19.6%)
  Azathioprine, n (%) 17 (15.9%)
  Cyclosporine A, n (%) 5 (4.7%)
  Mycophenolate mofetil, n (%) 2 (1.9%)
  Rituximab, n (%) 1 (0.9%)
  1. ACR American College of Rheumatology, ANA antinuclear antibodies, aPLs positivity for lupus anti-coagulant (LAC) and/or anticardiolipin and/or antiBeta2-GPI antibodies, PDN prednisolone (or equivalent), SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000, SLICC Systemic Lupus International Collaboration Clinics ()/SLICC
  2. aAccording to the International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 classification of lupus nephritis
  3. bAt diagnosis the SLICC Damage Index is equal to 0 by definition